Monday, July 27, 2026
Last week the surgical robotics market got a new heavyweight and lost a former favorite — on the same Wednesday.
J&J’s Ottava cleared the FDA on July 22. That same day, Vicarious Surgical’s shareholders voted to liquidate a company that had raised more than $425 million. Read those two headlines together and you have the industry’s operating thesis for 2026: the barrier to entry in high-capital medtech categories is no longer the technology, it’s the balance sheet and the commercial infrastructure behind it. The same logic showed up everywhere last week — Tempus buying its way into tumor-informed MRD rather than building it, Labcorp leaning on an acquired genetics portfolio to go direct-to-consumer, Edwards waiting on a coverage decision that will do more for volume than any product launch. Scale is the entry ticket now. Everything else is execution.
8 things to watch this week:
1. 🤖 J&J’s Ottava wins FDA De Novo authorization, ending Intuitive’s soft-tissue monopoly
After nearly a decade of delays, J&J secured De Novo marketing authorization for the Ottava Robotic Surgical System across ten general surgery procedures — the first soft-tissue platform to integrate its arms directly into the OR table, occupying 30–50% less space than boom- or cart-mounted systems. J&J is running a controlled launch with select U.S. customers and deliberately entered through general surgery, the less-penetrated segment where Ethicon’s install base and relationships are strongest. Both Intuitive and Medtronic shares declined on the news.
2. ⚰️ Vicarious Surgical shareholders vote to dissolve the company
Shareholders approved an assignment for the benefit of creditors — an alternative to bankruptcy — for a robot developer that raised more than $425 million from investors including Bill Gates ahead of its 2021 SPAC-era IPO. The company failed to secure additional funding or find a buyer and employed 26 people as of March. Same category, same week, opposite outcome: capital depth and channel access are now the gating factors in robotics, not the elegance of the architecture.
MedTech Dive
3. 🧭 Where does your commercialization actually stand? Two minutes to find out.
Device companies rarely fail on technology — they fail on sequencing. RŌG Health's free Commercial Readiness Check scores your readiness across six dimensions and shows where you're strongest and most exposed. If you want help closing a gap, it'll point you to the right starting place.
Sponsored by RŌG Health
4. 🩺 FDA names Dexcom the first participant in its TEMPO digital health pilot
CDRH selected Dexcom as the inaugural manufacturer in the Technology-Enabled Meaningful Patient Outcomes pilot, which pairs device oversight with real-world evidence generation and is explicitly tied to CMS Innovation Center’s ACCESS model — whose first cohort began this month. The Dexcom Glucose Health Program will combine G7 and Stelo data with nutrition, activity, sleep, and stress inputs. FDA says it’s still accepting statements of interest with no deadline, which makes this the clearest regulatory-plus-reimbursement on-ramp available to digital health right now.
MPO Magazine
5. ⚠️ FDA issues early alert as Boston Scientific pulls transcarotid catheter lots
Boston Scientific told customers on July 9 to stop using and return specific lots of the EnRoute Transcarotid Neuroprotection System and NPS Plus after reports of arterial sheath tip separation; the FDA posted its early alert Friday. One serious injury and no deaths have been reported, but retained tips may require endovascular or surgical retrieval, with embolism, stroke, TIA, restenosis, or thrombosis among the potential complications. The device came over in the $1.18 billion Silk Road Medical acquisition — a reminder that acquired product lines carry acquired quality histories.
Cardiovascular Business
6. 💓 Edwards posts strong TAVR quarter with a September coverage decision pending
Edwards raised its full-year outlook on strong structural heart performance, with TMTT revenue up roughly 47% year over year. The bigger catalyst is regulatory: CMS is expected to finalize its TAVR national coverage determination in September, and the draft policy opens a pathway to cover asymptomatic patients while modernizing heart-team requirements. PROGRESS data in moderate aortic stenosis follows at TCT this fall. For anyone modeling structural heart volume, September is the date that matters.
MedTech Dive
7. 🧬 Tempus to acquire Personalis for $1.5B, buying its way into tumor-informed MRD
Tempus agreed to pay $16.25 per share for the cancer-monitoring company, a 6% premium to the prior close and 28% to the unaffected 30-day VWAP, in a deal expected to close in late 2026 or early 2027. The strategic logic is straightforward — Tempus has been commercializing Personalis’ NeXT Personal test since 2023 and its own MRD capability isn’t tumor-informed, the methodology the market is converging on. Both stocks fell on the announcement, largely on the stock-based structure rather than the thesis.
MD+DI
8. 🧪 Labcorp launches a 163-gene direct-to-consumer hereditary risk panel
Marker by Labcorp analyzes 163 genes tied to more than 100 medically actionable conditions across hereditary cancer, cardiovascular, and metabolic categories, with licensed genetic counselors included and availability starting August 3 through Labcorp OnDemand. It’s the company’s first major consumer genetics product since absorbing Invitae’s portfolio in 2024, and Labcorp is explicitly positioning it against curiosity-driven DNA testing. The consumer channel is now a distribution strategy for clinical-grade diagnostics, not a novelty adjacent to one.
Fierce Biotech
Put your brand in front of 35,000+ medical device and med tech leaders each week. Contact us to learn more about sponsorship opportunities.
🧭 About The Pathway
The Pathway is a curated briefing for medical device leaders, focused on regulatory moves, product launches, partnerships, and market signals shaping the industry.
If this was useful, consider subscribing or sharing with a colleague who should be tracking these developments.
Some issues may include sponsored or partner content. Sponsorship does not influence editorial selection of third-party news items.